financetom
Business
financetom
/
Business
/
Conagra Brands forecasts annual revenue below estimates on tepid demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Conagra Brands forecasts annual revenue below estimates on tepid demand
Jul 11, 2024 6:09 AM

July 11 (Reuters) -

Conagra Brands ( CAG ) forecast annual revenue and profit

below estimates after missing quarterly revenue expectations on

Thursday, as high living costs prompted cash-strapped shoppers

to turn to cheaper alternatives for their at-home meals.

Shares of the company, which also missed quarterly revenue

estimates, were down about 4% in premarket trading.

The packaged food industry has been struggling with

lackluster volume recovery as higher living costs have squeezed

budgets, forcing cost-conscious consumers to look for even

cheaper alternatives despite preferring to eat at home over

dining out.

Despite reducing product prices to attract more cautious

spenders, the maker of Slim Jim beef jerky still experienced

sluggish demand in its frozen food and snacking businesses.

Conagra's total volumes decreased 1.8% in the fourth quarter

after falling 7.7% last year.

"Looking ahead, we expect a gradual waning of the

challenging industry trends seen throughout fiscal year 2024, as

consumers adapt and establish new reference prices," CEO Sean

Connolly said.

The company expects fiscal-year 2025 organic sales to

decrease between 1.5% to flat, compared with analysts' estimates

of 1.54% rise, as per LSEG data.

The company beat quarterly estimates for profit but

forecasts fiscal 2025 profit below estimates.

The Healthy Choice cereal maker expects annual profit per

share to be in the range of $2.60 to $2.65 compared to analysts'

estimates of $2.69 per share.

Conagra Brands ( CAG ) reported net sales of $2.91 billion for the

quarter ending May 26, below analysts' average estimates of

$2.93 billion, according to LSEG data.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Adidas Reports First Net Loss Since 1992, Warns of Inventory Problems in US
Adidas Reports First Net Loss Since 1992, Warns of Inventory Problems in US
Mar 13, 2024
09:05 AM EDT, 03/13/2024 (MT Newswires) -- Adidas on Wednesday reported its first annual loss since 1992 and warned that US sales would remain soft because of a surplus of stock among retailers. The German sportswear retailer reported a 2023 net loss from continuing operations of 58 million euros ($63.4 million), compared with net income of 254 million euros a...
HSBC Names Andrew Fullam CFO for the US, Americas
HSBC Names Andrew Fullam CFO for the US, Americas
Mar 13, 2024
09:06 AM EDT, 03/13/2024 (MT Newswires) -- HSBC Holdings ( HSBC ) said Wednesday that Andrew Fullam has been named as its chief financial officer for the US and the Americas. Fullam, who previously spent nearly two decades at HSBC ( HSBC ), rejoins the financial services giant from Wells Fargo where he was head of enterprise financial planning and...
Jacobs Solutions Wins $249 Million Contract for MacDill Air Force Base Support Services
Jacobs Solutions Wins $249 Million Contract for MacDill Air Force Base Support Services
Mar 13, 2024
09:10 AM EDT, 03/13/2024 (MT Newswires) -- Jacobs Solutions ( J ) said Wednesday it won a $249 million contract as a major subcontractor for the Chugach logistics and facility services joint venture for MacDill Air Force base. Under the terms, the company will provide facility engineering, asset management, and planning services to MacDill, Jacobs added. The project is slated...
US FDA staff flags safety concerns from J&J, Bristol's CAR-T therapies
US FDA staff flags safety concerns from J&J, Bristol's CAR-T therapies
Mar 13, 2024
March 13 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's ( JNJ ) and Bristol Myers Squibb's ( BMY ) cancer therapies as earlier treatments for blood cancer patients. Staff reviewers said that the pattern of early deaths observed in patients treated with both the therapies...
Copyright 2023-2026 - www.financetom.com All Rights Reserved